RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression of inflammatory cytokines.
- Mechanism
- Curator reviewed
RDP58 disrupts cellular responses signaled through the Toll-like and tumor necrosis factor (TNF) receptor families and occludes important signal transduction pathways involved in inflammation, inhibiting the production of tumor necrosis factor alpha (TNFalpha), interferon-gamma, interleukin (IL)-2, IL-6, and IL-12. These pro-inflammatory cytokines are thought to be involved in the pathogenesis of several inflammatory and autoimmune diseases, including atopic dermatitis and psoriasis
- Primary indication
- Investigated for use/treatment in ulcerative colitis and crohn's disease.Curator reviewed
- Code names
- RDP58
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with RDP58, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account